{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:37:25Z","timestamp":1789792645978,"version":"4.0.1"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12069-2","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:01:27Z","timestamp":1780732887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HSP70-targeting TKD-functionalized smart micelles for membrane\u2212guided precision breast cancer therapy: a review"],"prefix":"10.1007","volume":"53","author":[{"given":"Manisha S.","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rohith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevan","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mallamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"7","key":"12069_CR1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3390\/biomedicines13071691","volume":"13","author":"H Sabit","year":"2025","unstructured":"Sabit H, Rashwan S, Albrahim Y, Wadan AHS, Radwan F, Alqosaibi AI et al (2025) Targeting Resistance Pathways in Breast Cancer Through Precision Oncology: Nanotechnology and Immune Modulation Approaches. Biomedicines 13(7):1691. https:\/\/doi.org\/10.3390\/biomedicines13071691","journal-title":"Biomedicines"},{"key":"12069_CR2","doi-asserted-by":"publisher","first-page":"731535","DOI":"10.3389\/fonc.2021.731535","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Zhan Z, Yin X, Fu S, Deng X (2021) Targeted Therapeutic Strategies for Triple-Negative Breast Cancer. Front Oncol 11:731535. https:\/\/doi.org\/10.3389\/fonc.2021.731535","journal-title":"Front Oncol"},{"issue":"6","key":"12069_CR3","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.3390\/jcm15062311","volume":"15","author":"A Crintea","year":"2026","unstructured":"Crintea A, Boc\u0219an CI, Jianu EM, \u0218ovrea AS, Munteanu C, Kubelac MP et al (2026) Overcoming Chemotherapy Resistance in Triple-Negative Breast Cancer with Nanocarrier-Delivered siRNA Therapeutics. J Clin Med 15(6):2311. https:\/\/doi.org\/10.3390\/jcm15062311","journal-title":"J Clin Med"},{"issue":"15","key":"12069_CR4","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.3390\/ijms26157119","volume":"26","author":"F Postigo-Corrales","year":"2025","unstructured":"Postigo-Corrales F, Beltr\u00e1n-Videla A, L\u00e1zaro-S\u00e1nchez AD, Hurtado AM, Conesa-Zamora P, Arroyo AB et al (2025) Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions. Int J Mol Sci 26(15):7119. https:\/\/doi.org\/10.3390\/ijms26157119","journal-title":"Int J Mol Sci"},{"key":"12069_CR5","doi-asserted-by":"publisher","first-page":"118552","DOI":"10.1016\/j.ejmech.2025.118552","volume":"304","author":"LT Li","year":"2026","unstructured":"Li LT, Yang YY, Zhang SC, Zhang JF, Gao C, Zhu X, Li XY (2026) Targeting HSP70 protein-protein interactions for cancer precision Therapy: Mechanisms, structures, and inhibitor strategies. Eur J Med Chem 304:118552. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118552","journal-title":"Eur J Med Chem"},{"key":"12069_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cytogfr.2025.09.002","volume":"86","author":"K Hachani","year":"2025","unstructured":"Hachani K, Ghanem M, Pockley AG, Wollenberg B, Bashiri Dezfouli A, Multhoff G (2025) Heat shock protein 70 (Hsp70) as a target for advancing immunotherapy in solid tumors. Cytokine Growth Factor Rev 86:83\u201395. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.09.002","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"12069_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3390\/cells14070509","volume":"14","author":"MK Singh","year":"2025","unstructured":"Singh MK, Han S, Ju S, Ranbhise JS, Ha J, Yeo SG et al (2025) Hsp70: A Multifunctional Chaperone in Maintaining Proteostasis and Its Implications in Human Disease. Cells 14(7):509. https:\/\/doi.org\/10.3390\/cells14070509","journal-title":"Cells"},{"issue":"1738","key":"12069_CR8","doi-asserted-by":"publisher","first-page":"20160526","DOI":"10.1098\/rstb.2016.0526","volume":"373","author":"M Shevtsov","year":"2018","unstructured":"Shevtsov M, Huile G, Multhoff G (2018) Membrane heat shock protein 70: a theranostic target for cancer therapy. Philos Trans R Soc B Biol Sci 373(1738):20160526. https:\/\/doi.org\/10.1098\/rstb.2016.0526","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"12069_CR9","doi-asserted-by":"publisher","unstructured":"Ozcan G, Korkaya H The Role of HSP70 in Regulation of Breast Cancer Stem Cells and Apoptotic Pathway. In: Carafa V (ed) Biochemistry [Internet]. IntechOpen; 2025 [cited 2026 Apr 5]. https:\/\/www.intechopen.com\/chapters\/1214124https:\/\/doi.org\/10.5772\/intechopen.1009789","DOI":"10.5772\/intechopen.1009789"},{"key":"12069_CR10","doi-asserted-by":"publisher","first-page":"112584","DOI":"10.1016\/j.intimp.2024.112584","volume":"138","author":"S Kumar","year":"2024","unstructured":"Kumar S, Mohan V, Kant Singh R, Kumar Gautam P, Kumar S, Shukla A et al (2024) Tumor-derived Hsp70-CD14 interaction enhances the antitumor potential of cytotoxic T cells by activating tumor-associated macrophages to express CC chemokines and CD40 costimulatory molecules. Int Immunopharmacol 138:112584. https:\/\/doi.org\/10.1016\/j.intimp.2024.112584","journal-title":"Int Immunopharmacol"},{"key":"12069_CR11","doi-asserted-by":"publisher","first-page":"1500880","DOI":"10.3389\/fcell.2024.1500880","volume":"12","author":"S Ghai","year":"2025","unstructured":"Ghai S, Shrestha R, Su KH (2025) HSF1 at the crossroads of chemoresistance: from current insights to future horizons in cell death mechanisms. Front Cell Dev Biol 12:1500880. https:\/\/doi.org\/10.3389\/fcell.2024.1500880","journal-title":"Front Cell Dev Biol"},{"issue":"18","key":"12069_CR12","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.3390\/cancers13184721","volume":"13","author":"M Linder","year":"2021","unstructured":"Linder M, Pogge Von Strandmann E (2021) The Role of Extracellular HSP70 in the Function of Tumor-Associated Immune Cells. Cancers 13(18):4721. https:\/\/doi.org\/10.3390\/cancers13184721","journal-title":"Cancers"},{"issue":"6","key":"12069_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.18502\/ijaai.v18i6.2172","volume":"18","author":"MA Vostakolaei","year":"2019","unstructured":"Vostakolaei MA, Abdolalizadeh J, Hejazi MS, Kordi S, Molavi O (2019) Hsp70 in Cancer: Partner or Traitor to Immune System. Iran J Allergy Asthma Immunol 18(6):589\u2013604. https:\/\/doi.org\/10.18502\/ijaai.v18i6.2172","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"1","key":"12069_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/ijms27010150","volume":"27","author":"A Dmitrieva","year":"2025","unstructured":"Dmitrieva A, Ryzhov V, Marchenko Y, Deriglazov V, Nikolaev B, Yakovleva L et al (2025) Cellulose-Encapsulated Magnetite Nanoparticles for Spiking of Tumor Cells Positive for the Membrane-Bound Hsp70. Int J Mol Sci 27(1):150. https:\/\/doi.org\/10.3390\/ijms27010150","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"12069_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijpharm.2015.12.013","volume":"498","author":"Y Meng","year":"2016","unstructured":"Meng Y, Wang S, Li C, Qian M, Zheng Y, Yan X et al (2016) TKD peptide as a ligand targeting drug delivery systems to memHsp70-positive breast cancer. Int J Pharm 498(1\u20132):40\u201348. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.12.013","journal-title":"Int J Pharm"},{"key":"12069_CR16","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.2147\/IJN.S376358","volume":"17","author":"AK Mohan","year":"2022","unstructured":"Mohan AK, Kumar MM, Kumar TRS, Multi-Layered GSV (2022) Nanoparticles Functionalized with TKD Peptide for Targeted Delivery of Pep5 to Breast Tumor Cells and Spheroids. Int J Nanomed 17:5581\u20135600. https:\/\/doi.org\/10.2147\/IJN.S376358","journal-title":"Int J Nanomed"},{"key":"12069_CR17","doi-asserted-by":"publisher","first-page":"1587414","DOI":"10.3389\/fimmu.2025.1587414","volume":"16","author":"B Zhang","year":"2025","unstructured":"Zhang B, Qi R (2025) The dual-function of HSP70 in immune response and tumor immunity: from molecular regulation to therapeutic innovations. Front Immunol 16:1587414. https:\/\/doi.org\/10.3389\/fimmu.2025.1587414","journal-title":"Front Immunol"},{"issue":"2","key":"12069_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.20517\/cdr.2023.16","volume":"6","author":"X Sun","year":"2023","unstructured":"Sun X, Zhao P, Lin J, Chen K, Shen J (2023) Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system. Cancer Drug Resist 6(2):390\u2013415. https:\/\/doi.org\/10.20517\/cdr.2023.16","journal-title":"Cancer Drug Resist"},{"issue":"9","key":"12069_CR19","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.3390\/pharmaceutics14091860","volume":"14","author":"V Junnuthula","year":"2022","unstructured":"Junnuthula V, Kolimi P, Nyavanandi D, Sampathi S, Vora LK, Dyawanapelly S (2022) Polymeric Micelles for Breast Cancer Therapy: Recent Updates, Clinical Translation and Regulatory Considerations. Pharmaceutics 14(9):1860. https:\/\/doi.org\/10.3390\/pharmaceutics14091860","journal-title":"Pharmaceutics"},{"issue":"10","key":"12069_CR20","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.7150\/thno.38069","volume":"10","author":"P Mi","year":"2020","unstructured":"Mi P (2020) Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics 10(10):4557\u20134588. https:\/\/doi.org\/10.7150\/thno.38069","journal-title":"Theranostics"},{"issue":"1","key":"12069_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","volume":"24","author":"H Sabit","year":"2025","unstructured":"Sabit H, Pawlik TM, Radwan F, Abdel-Hakeem M, Abdel-Ghany S, Wadan AHS et al (2025) Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. Mol Cancer 24(1):160. https:\/\/doi.org\/10.1186\/s12943-025-02357-z","journal-title":"Mol Cancer"},{"issue":"6","key":"12069_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/pharmaceutics17060779","volume":"17","author":"A Jadhav","year":"2025","unstructured":"Jadhav A, Nagaraj K (2025) Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal. Pharmaceutics 17(6):779. https:\/\/doi.org\/10.3390\/pharmaceutics17060779","journal-title":"Pharmaceutics"},{"issue":"23","key":"12069_CR23","doi-asserted-by":"publisher","first-page":"1706759","DOI":"10.1002\/adma.201706759","volume":"30","author":"RH Fang","year":"2018","unstructured":"Fang RH, Kroll AV, Gao W, Zhang L (2018) Cell Membrane Coating Nanotechnology. Adv Mater 30(23):1706759. https:\/\/doi.org\/10.1002\/adma.201706759","journal-title":"Adv Mater"},{"key":"12069_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","volume":"108","author":"JI Hare","year":"2017","unstructured":"Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST (2017) Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv Drug Deliv Rev 108:25\u201338. https:\/\/doi.org\/10.1016\/j.addr.2016.04.025","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"12069_CR25","doi-asserted-by":"publisher","first-page":"e70040","DOI":"10.1002\/psc.70040","volume":"31","author":"A Armstrong","year":"2025","unstructured":"Armstrong A, Coburn F, Nsereko Y, Al Musaimi O (2025) Peptide-Drug Conjugates: A New Hope for Cancer. J Pept Sci 31(8):e70040. https:\/\/doi.org\/10.1002\/psc.70040","journal-title":"J Pept Sci"},{"issue":"12","key":"12069_CR26","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3390\/ph18121772","volume":"18","author":"S Jacob","year":"2025","unstructured":"Jacob S, Varkey NR, Boddu SHS, Gorain B, Rao R, Nair AB (2025) Advances in Lipid-Polymer Hybrid Nanoparticles: Design Strategies, Functionalization, Oncological and Non-Oncological Clinical Prospects. Pharmaceuticals 18(12):1772. https:\/\/doi.org\/10.3390\/ph18121772","journal-title":"Pharmaceuticals"},{"issue":"3","key":"12069_CR27","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Mitragotri S (2019) Nanoparticles in the clinic: An update. Bioeng Transl Med 4(3):e10143. https:\/\/doi.org\/10.1002\/btm2.10143","journal-title":"Bioeng Transl Med"},{"issue":"10","key":"12069_CR28","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","volume":"33","author":"D Bobo","year":"2016","unstructured":"Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR (2016) Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res 33(10):2373\u20132387. https:\/\/doi.org\/10.1007\/s11095-016-1958-5","journal-title":"Pharm Res"},{"issue":"7","key":"12069_CR29","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1007\/s11033-020-05641-x","volume":"47","author":"E K\u0131yga","year":"2020","unstructured":"K\u0131yga E, \u015eengelen A, Ad\u0131g\u00fczel Z, \u00d6nay U\u00e7ar E (2020) Investigation of the role of quercetin as a heat shock protein inhibitor on apoptosis in human breast cancer cells. Mol Biol Rep 47(7):4957\u20134967. https:\/\/doi.org\/10.1007\/s11033-020-05641-x","journal-title":"Mol Biol Rep"},{"issue":"7","key":"12069_CR30","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s13346-022-01241-3","volume":"13","author":"I Rana","year":"2023","unstructured":"Rana I, Oh J, Baig J, Moon JH, Son S, Nam J (2023) Nanocarriers for cancer nano-immunotherapy. Drug Deliv Transl Res 13(7):1936\u20131954. https:\/\/doi.org\/10.1007\/s13346-022-01241-3","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"12069_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J et al (2023) Advances in immunotherapy for triple-negative breast cancer. Mol Cancer 22(1):145. https:\/\/doi.org\/10.1186\/s12943-023-01850-7","journal-title":"Mol Cancer"},{"issue":"3","key":"12069_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C et al (2022) Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 387(3):217\u2013226. https:\/\/doi.org\/10.1056\/NEJMoa2202809","journal-title":"N Engl J Med"},{"issue":"15","key":"12069_CR33","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M et al (2024) Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol 42(15):1738\u20131744. https:\/\/doi.org\/10.1200\/JCO.23.01409","journal-title":"J Clin Oncol"},{"issue":"10","key":"12069_CR34","doi-asserted-by":"publisher","first-page":"S389","DOI":"10.1016\/j.jtho.2024.09.704","volume":"19","author":"N Frost","year":"2024","unstructured":"Frost N, Ghori R, Roy A, Nunes AT, Yang JCH (2024) P4.11D.02 Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS\u2009\u2265\u200950%. J Thorac Oncol 19(10):S389\u2013S390. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.704","journal-title":"J Thorac Oncol"},{"key":"12069_CR35","doi-asserted-by":"publisher","first-page":"117929","DOI":"10.1016\/j.bcp.2026.117929","volume":"250","author":"A Mussa","year":"2026","unstructured":"Mussa A, Hamid M, Talib M, Ehinnou I, Bragoli A, Hajissa K et al (2026) Novel targeted therapies and immunological strategies for breast cancer treatment. Biochem Pharmacol 250:117929. https:\/\/doi.org\/10.1016\/j.bcp.2026.117929","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 1","key":"12069_CR36","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.breast.2022.02.003","volume":"62","author":"CH Barrios","year":"2022","unstructured":"Barrios CH (2022) Global challenges in breast cancer detection and treatment. Breast 62(Suppl 1):S3\u2013S6. https:\/\/doi.org\/10.1016\/j.breast.2022.02.003","journal-title":"Breast"},{"issue":"3","key":"12069_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/cells9030587","volume":"9","author":"Z Albakova","year":"2020","unstructured":"Albakova Z, Armeev GA, Kanevskiy LM, Kovalenko EI, Sapozhnikov AM (2020) HSP70 Multi-Functionality in Cancer. Cells 9(3):587. https:\/\/doi.org\/10.3390\/cells9030587","journal-title":"Cells"},{"issue":"12","key":"12069_CR38","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.3390\/biomedicines13123073","volume":"13","author":"D Simancas-Racines","year":"2025","unstructured":"Simancas-Racines D, Rom\u00e1n-Galeano NM, V\u00e1squez JP, Jima Gavilanes D, Vijayan R, Reytor-Gonz\u00e1lez C (2025) Liquid Biopsy and Multi-Omic Biomarkers in Breast Cancer: Innovations in Early Detection, Therapy Guidance, and Disease Monitoring. Biomedicines 13(12):3073. https:\/\/doi.org\/10.3390\/biomedicines13123073","journal-title":"Biomedicines"},{"issue":"1","key":"12069_CR39","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1186\/s12885-023-11674-9","volume":"23","author":"K Singh","year":"2023","unstructured":"Singh K, Gautam PK (2023) Macrophage infiltration in 3D cancer spheroids to recapitulate the TME and unveil interactions within cancer cells and macrophages to modulate chemotherapeutic drug efficacy. BMC Cancer 23(1):1201. https:\/\/doi.org\/10.1186\/s12885-023-11674-9","journal-title":"BMC Cancer"},{"issue":"7","key":"12069_CR40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3390\/cells14070509","volume":"14","author":"MK Singh","year":"2025","unstructured":"Singh MK, Han S, Ju S, Ranbhise JS, Ha J, Yeo SG et al (2025) Hsp70: A Multifunctional Chaperone in Maintaining Proteostasis and Its Implications in Human Disease. Cells 14(7):509. https:\/\/doi.org\/10.3390\/cells14070509","journal-title":"Cells"},{"key":"12069_CR41","doi-asserted-by":"publisher","first-page":"942828","DOI":"10.3389\/fcell.2022.942828","volume":"10","author":"S Du","year":"2022","unstructured":"Du S, Liu Y, Yuan Y, Wang Y, Chen Y, Wang S et al (2022) Advances in the study of HSP70 inhibitors to enhance the sensitivity of tumor cells to radiotherapy. Front Cell Dev Biol 10:942828. https:\/\/doi.org\/10.3389\/fcell.2022.942828","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"12069_CR42","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1158\/2767-9764.CRC-24-0094","volume":"4","author":"M Shevtsov","year":"2024","unstructured":"Shevtsov M, Bobkov D, Yudintceva N, Likhomanova R, Kim A, Fedorov E et al (2024) Membrane-bound Heat Shock Protein mHsp70 Is Required for Migration and Invasion of Brain Tumors. Cancer Res Commun 4(8):2025\u20132044. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0094","journal-title":"Cancer Res Commun"},{"issue":"6","key":"12069_CR43","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.3390\/cancers15061903","volume":"15","author":"M Yamaguchi-Tanaka","year":"2023","unstructured":"Yamaguchi-Tanaka M, Takagi K, Miki Y, Sato A, Iwabuchi E, Miyashita M, Suzuki T (2023) The Pro-Tumorigenic Role of Chemotherapy-Induced Extracellular HSP70 from Breast Cancer Cells via Intratumoral Macrophages. Cancers (Basel) 15(6):1903. https:\/\/doi.org\/10.3390\/cancers15061903","journal-title":"Cancers (Basel)"},{"issue":"5","key":"12069_CR44","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1002\/jcp.30132","volume":"236","author":"MA Vostakolaei","year":"2021","unstructured":"Vostakolaei MA, Hatami-Baroogh L, Babaei G, Molavi O, Kordi S, Abdolalizadeh J (2021) Hsp70 in cancer: A double agent in the battle between survival and death. J Cell Physiol 236(5):3420\u20133444. https:\/\/doi.org\/10.1002\/jcp.30132","journal-title":"J Cell Physiol"},{"issue":"3","key":"12069_CR45","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.21873\/anticanres.12384","volume":"38","author":"DT Dimas","year":"2018","unstructured":"Dimas DT, Perlepe CD, Sergentanis TN, Misitzis I, Kontzoglou K, Patsouris E, Kouraklis G, Psaltopoulou T, Nonni A (2018) The Prognostic Significance of Hsp70\/Hsp90 Expression in Breast Cancer: A Systematic Review and Meta-analysis. Anticancer Res 38(3):1551\u20131562. https:\/\/doi.org\/10.21873\/anticanres.12384","journal-title":"Anticancer Res"},{"issue":"1","key":"12069_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40814-020-00577-2","volume":"6","author":"G Chanteloup","year":"2020","unstructured":"Chanteloup G, Cordonnier M, Isambert N, Bertaut A, Marcion G, Garrido C et al (2020) Membrane-bound exosomal HSP70 as a biomarker for detection and monitoring of malignant solid tumours: a pilot study. Pilot Feasibility Stud 6(1):35. https:\/\/doi.org\/10.1186\/s40814-020-00577-2","journal-title":"Pilot Feasibility Stud"},{"key":"12069_CR47","doi-asserted-by":"publisher","unstructured":"R\u00e9role AL, Gobbo J, De Thonel A, Schmitt E, Pais De Barros JP, Hammann A et al (2023) Data from Peptides and Aptamers Targeting HSP70: A Novel Approach for Anticancer Chemotherapy. American Association for Cancer Research [Internet]. 2023 Mar 30 [cited 2026 Apr 28]. https:\/\/aacr.figshare.com\/collections\/Data_from_Peptides_and_Aptamers_Targeting_HSP70_A_Novel_Approach_for_Anticancer_Chemotherapy\/6501842https:\/\/doi.org\/10.1158\/0008-5472.c.6501842","DOI":"10.1158\/0008-5472.c.6501842"},{"key":"12069_CR48","doi-asserted-by":"publisher","unstructured":"Yuan R, Liu R, Shao F, Cai Z, Fang Y, Chen K, Zhou Y, Ye T, Li G (2026 Apr) Oncolytic Vaccinia Virus-HSP70-shRNA Amplifies Viral Replication, ROS\/Autophagy, and Immunity to Fight Colorectal Cancer. Cancer Sci 23. https:\/\/doi.org\/10.1111\/cas.70389","DOI":"10.1111\/cas.70389"},{"issue":"8Supplement1","key":"12069_CR49","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/1538-7445.AM2025-3958","volume":"85","author":"AB Caglayan","year":"2025","unstructured":"Caglayan AB, Alkan FK, Alkan HK, Jones C, Kurtulus SO, Ishaya E et al (2025) Abstract 3958: Targeting HSP70 enhances immunotherapy efficacy in triple-negative breast cancer by modulating tumor intrinsic and immunosuppressive pathways. Cancer Res 85(8Supplement1):3958\u20133958. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-3958","journal-title":"Cancer Res"},{"key":"12069_CR50","doi-asserted-by":"publisher","first-page":"154127","DOI":"10.1016\/j.prp.2022.154127","volume":"238","author":"AC Peterko","year":"2022","unstructured":"Peterko AC, Rajkovi\u0107-Molek K, Guli\u0107 T, Vujaklija DV, Lovasi\u0107 IB, Lovasi\u0107 F et al (2022) HSP70 In triple negative breast cancer: Prognostic value and clinical significance. Pathol - Res Pract 238:154127. https:\/\/doi.org\/10.1016\/j.prp.2022.154127","journal-title":"Pathol - Res Pract"},{"issue":"5","key":"12069_CR51","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3390\/biomedicines13051034","volume":"13","author":"KY Wu","year":"2025","unstructured":"Wu KY, Crucho A, Su M, Chen ST, Hung CH, Kou YL et al (2025) Synergistic Anticancer Activity of HSP70 Inhibitor and Doxorubicin in Gain-of-Function Mutated p53 Breast Cancer Cells. Biomedicines 13(5):1034. https:\/\/doi.org\/10.3390\/biomedicines13051034","journal-title":"Biomedicines"},{"key":"12069_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030622","author":"VV Veselov","year":"2022","unstructured":"Veselov VV, Nosyrev AE, Jicsinszky L, Alyautdin RN, Cravotto G (2022) Targeted Delivery Methods for Anticancer Drugs. Cancers. https:\/\/doi.org\/10.3390\/cancers14030622","journal-title":"Cancers"},{"issue":"44","key":"12069_CR53","doi-asserted-by":"publisher","first-page":"e10802","DOI":"10.1002\/advs.202510802","volume":"12","author":"T Fang","year":"2025","unstructured":"Fang T, Li L, Tariq Muhseen Z, Lane LA, Cai H, Butch CJ et al (2025) Strategic Timing of Gene Silencing: Cellular Kinetics-Based Administration of siRNA for Optimized Photothermal Cancer Treatment. Adv Sci 12(44):e10802. https:\/\/doi.org\/10.1002\/advs.202510802","journal-title":"Adv Sci"},{"key":"12069_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/3267207","volume":"2019","author":"JK Das","year":"2019","unstructured":"Das JK, Xiong X, Ren X, Yang JM, Song J (2019) Heat Shock Proteins in Cancer Immunotherapy. J Oncol 2019:1\u20139. https:\/\/doi.org\/10.1155\/2019\/3267207","journal-title":"J Oncol"},{"issue":"8","key":"12069_CR55","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.1021\/acsami.8b21784","volume":"11","author":"B Li","year":"2019","unstructured":"Li B, Wang Y, He J (2019) Gold Nanorods-Based Smart Nanoplatforms for Synergic Thermotherapy and Chemotherapy of Tumor Metastasis. ACS Appl Mater Interfaces 11(8):7800\u20137811. https:\/\/doi.org\/10.1021\/acsami.8b21784","journal-title":"ACS Appl Mater Interfaces"},{"key":"12069_CR56","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/978-1-4939-7477-1_22","volume":"1709","author":"S Stangl","year":"2018","unstructured":"Stangl S, Foulds GA, Fellinger H, Pilkington GJ, Pockley AG, Multhoff G (2018) Immunohistochemical and Flow Cytometric Analysis of Intracellular and Membrane-Bound Hsp70, as a Putative Biomarker of Glioblastoma Multiforme, Using the cmHsp70.1 Monoclonal Antibody. Methods Mol Biol 1709:307\u2013320. http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-1-4939-7477-1_22\u00a0","journal-title":"Methods Mol Biol"},{"issue":"3","key":"12069_CR57","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.clbc.2020.11.005","volume":"21","author":"HH Fahim","year":"2021","unstructured":"Fahim HH, Mohamed G, Safwat G, Abo-bakr A, Ibraheem MH, Al-Mofty S et al (2021) HSP70 as a Diagnostic and Prognostic Marker in Egyptian Women With Breast Cancer. Clin Breast Cancer 21(3):e177\u2013e188. https:\/\/doi.org\/10.1016\/j.clbc.2020.11.005","journal-title":"Clin Breast Cancer"},{"issue":"12","key":"12069_CR58","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.3390\/cells10123446","volume":"10","author":"AE Kabakov","year":"2021","unstructured":"Kabakov AE, Gabai VL (2021) HSP70s in Breast Cancer: Promoters of Tumorigenesis and Potential Targets\/Tools for Therapy. Cells 10(12):3446. https:\/\/doi.org\/10.3390\/cells10123446","journal-title":"Cells"},{"issue":"4","key":"12069_CR59","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3390\/cancers15041167","volume":"15","author":"Z Wu","year":"2023","unstructured":"Wu Z, Stangl S, Hernandez-Schnelzer A, Wang F, Hasanzadeh Kafshgari M, Bashiri Dezfouli A, Multhoff G (2023) Functionalized Hybrid Iron Oxide-Gold Nanoparticles Targeting Membrane Hsp70 Radiosensitize Triple-Negative Breast Cancer Cells by ROS-Mediated Apoptosis. Cancers (Basel) 15(4):1167. https:\/\/doi.org\/10.3390\/cancers15041167","journal-title":"Cancers (Basel)"},{"key":"12069_CR60","doi-asserted-by":"publisher","unstructured":"Gobbo J, Marcion G, Cordonnier M, Dias AMM, Pernet N, Hammann A, Richaud S, Mjahed H, Isambert N, Clausse V, R\u00e9b\u00e9 C, Bertaut A, Goussot V, Lirussi F, Ghiringhelli F, de Thonel A, Fumoleau P, Seigneuric R, Garrido C (2015) Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. J Natl Cancer Inst 108(3). https:\/\/doi.org\/10.1093\/jnci\/djv330","DOI":"10.1093\/jnci\/djv330"},{"issue":"2","key":"12069_CR61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12032-014-0453-2","volume":"32","author":"J Diao","year":"2015","unstructured":"Diao J, Yang X, Song X, Chen S, He Y, Wang Q et al (2015) Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3. Med Oncol 32(2):35. https:\/\/doi.org\/10.1007\/s12032-014-0453-2","journal-title":"Med Oncol"},{"issue":"2","key":"12069_CR62","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1172\/JCI40483","volume":"120","author":"F De Chalmin","year":"2010","unstructured":"Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, R\u00e9b\u00e9 C, Ghiringhelli F (2010) Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 120(2):457\u2013471. https:\/\/doi.org\/10.1172\/JCI40483","journal-title":"J Clin Invest"},{"issue":"6","key":"12069_CR63","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/0265673021000017109","volume":"18","author":"G Multhoff","year":"2002","unstructured":"Multhoff G (2002) Activation of natural killer cells by heat shock protein 70. Int J Hyperth 18(6):576\u2013585. https:\/\/doi.org\/10.1080\/0265673021000017109","journal-title":"Int J Hyperth"},{"issue":"3","key":"12069_CR64","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/curroncol32030143","volume":"32","author":"T Moura","year":"2025","unstructured":"Moura T, Laranjeira P, Caramelo O, Gil AM, Paiva A (2025) Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells. Curr Oncol 32(3):143. https:\/\/doi.org\/10.3390\/curroncol32030143","journal-title":"Curr Oncol"},{"key":"12069_CR65","doi-asserted-by":"publisher","first-page":"1421629","DOI":"10.3389\/fcell.2024.1421629","volume":"12","author":"AL Capatina","year":"2024","unstructured":"Capatina AL, Malcolm JR, Stenning J, Moore RL, Bridge KS, Brackenbury WJ et al (2024) Hypoxia-induced epigenetic regulation of breast cancer progression and the tumour microenvironment. Front Cell Dev Biol 12:1421629. https:\/\/doi.org\/10.3389\/fcell.2024.1421629","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"12069_CR66","doi-asserted-by":"publisher","first-page":"e004793","DOI":"10.1136\/jitc-2022-004793","volume":"10","author":"K Kaneko","year":"2022","unstructured":"Kaneko K, Acharya CR, Nagata H, Yang X, Hartman ZC, Hobeika A et al (2022) Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1\/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers. J Immunother Cancer 10(9):e004793. https:\/\/doi.org\/10.1136\/jitc-2022-004793","journal-title":"J Immunother Cancer"},{"key":"12069_CR67","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2340\/1651-226X.2024.33008","volume":"63","author":"M Otterlei Fj\u00f8rtoft","year":"2024","unstructured":"Otterlei Fj\u00f8rtoft M, Huse K, Rye IH (2024) The Tumor Immune Microenvironment in Breast Cancer Progression. Acta Oncol 63:359\u2013367. https:\/\/doi.org\/10.2340\/1651-226X.2024.33008","journal-title":"Acta Oncol"},{"issue":"1","key":"12069_CR68","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41421-024-00699-4","volume":"10","author":"J Yang","year":"2024","unstructured":"Yang J, Wang QL, Wang GN, Ye JC, Li ZQ, Wang JY et al (2024) A pan-KRAS degrader for the treatment of KRAS-mutant cancers. Cell Discov 10(1):70. https:\/\/doi.org\/10.1038\/s41421-024-00699-4","journal-title":"Cell Discov"},{"issue":"4","key":"12069_CR69","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/life14040489","volume":"14","author":"A Marques","year":"2024","unstructured":"Marques A, Costa P, Velho S, Amaral M (2024) Analytical Techniques for Characterizing Tumor-Targeted Antibody-Functionalized Nanoparticles. Life 14(4):489. https:\/\/doi.org\/10.3390\/life14040489","journal-title":"Life"},{"issue":"14","key":"12069_CR70","doi-asserted-by":"publisher","first-page":"2305998","DOI":"10.1002\/advs.202305998","volume":"11","author":"M Yazdi","year":"2024","unstructured":"Yazdi M, Hasanzadeh Kafshgari M, Khademi Moghadam F, Zarezade V, Oellinger R, Khosravi M et al (2024) Crosstalk Between NK Cell Receptors and Tumor Membrane Hsp70-Derived Peptide: A Combined Computational and Experimental Study. Adv Sci 11(14):2305998. https:\/\/doi.org\/10.1002\/advs.202305998","journal-title":"Adv Sci"},{"key":"12069_CR71","doi-asserted-by":"publisher","first-page":"1847197","DOI":"10.1155\/adpp\/1847197","volume":"2025","author":"AA Roy","year":"2025","unstructured":"Roy AA, Pandey A, Dhas N, Hegde MM, Parekh HS, Andugulapati SB, Nandakumar K, Satish Rao BS, Mutalik S (2025) The Confluence of Nanotechnology and Heat Shock Protein 70 in Pioneering Glioblastoma Multiforme Therapy: Forging Pathways Towards Precision Targeting and Transformation. Adv Pharmacol Pharm Sci 2025:1847197. https:\/\/doi.org\/10.1155\/adpp\/1847197","journal-title":"Adv Pharmacol Pharm Sci"},{"issue":"13","key":"12069_CR72","doi-asserted-by":"publisher","first-page":"10967","DOI":"10.1021\/acs.jmedchem.4c00511","volume":"67","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Fan Y, Liu S, Guan Y, Wan J, Ren Q et al (2024) Development of Peptide Paratope Mimics Derived from the Anti-ROR1 Antibody and Long-Acting Peptide\u2013Drug Conjugates for Targeted Cancer Therapy. J Med Chem 67(13):10967\u201310985. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00511","journal-title":"J Med Chem"},{"issue":"1","key":"12069_CR73","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/cancers15010004","volume":"15","author":"Rodr\u00edguezA Guzm\u00e1n","year":"2022","unstructured":"Guzm\u00e1n Rodr\u00edguezA, Sabl\u00f3n Carrazana M, Rodr\u00edguez Tanty C, Malessy MJA, Fuentes G, Cruz LJ (2022) Smart Polymeric Micelles for Anticancer Hydrophobic Drugs. Cancers 15(1):4. https:\/\/doi.org\/10.3390\/cancers15010004","journal-title":"Cancers"},{"key":"12069_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IJN.S495387","volume":"20","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lin M, Fan T, Zhou M, Yin R, Wang X (2025) Advances of Stimuli-Responsive Amphiphilic Copolymer Micelles in Tumor Therapy. Int J Nanomed 20:1\u201324. https:\/\/doi.org\/10.2147\/IJN.S495387","journal-title":"Int J Nanomed"},{"issue":"3","key":"12069_CR75","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3390\/pharmaceutics15030733","volume":"15","author":"NN Bayram","year":"2023","unstructured":"Bayram NN, Ulu GT, Abdulhadi NA, G\u00fcrdap S, \u0130\u015fo\u011flu \u0130A, Baran Y et al (2023) HER2-Specific Peptide (LTVSPWY) and Antibody (Herceptin) Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study. Pharmaceutics 15(3):733. https:\/\/doi.org\/10.3390\/pharmaceutics15030733","journal-title":"Pharmaceutics"},{"issue":"8","key":"12069_CR76","doi-asserted-by":"publisher","first-page":"9436","DOI":"10.1021\/acsami.0c18282","volume":"13","author":"Y Tan","year":"2021","unstructured":"Tan Y, Li Y, Qu YX, Su Y, Peng Y, Zhao Z et al (2021) Aptamer-Peptide Conjugates as Targeted Chemosensitizers for Breast Cancer Treatment. ACS Appl Mater Interfaces 13(8):9436\u20139444. https:\/\/doi.org\/10.1021\/acsami.0c18282","journal-title":"ACS Appl Mater Interfaces"},{"key":"12069_CR77","doi-asserted-by":"publisher","first-page":"124487","DOI":"10.1016\/j.ijpharm.2024.124487","volume":"662","author":"T Nourollahian","year":"2024","unstructured":"Nourollahian T, Taghavi S, Abnous K, Taghdisi SM, Nekooei S, Ramezani M et al (2024) Targeted doxorubicin-loaded core\u2013shell copper peroxide-mesoporous silica nanoparticles for combination of ferroptosis and chemotherapy of metastatic breast cancer. Int J Pharm 662:124487. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124487","journal-title":"Int J Pharm"},{"issue":"3","key":"12069_CR78","doi-asserted-by":"publisher","first-page":"416","DOI":"10.5530\/jyp.2024.16.54","volume":"16","author":"N Shobhana","year":"2024","unstructured":"Shobhana N, Goudanavar P, Mallamma T, Akondi BR (2024) Magnetic Nano-Particles: Properties, Synthesis and its Application in Treatment of Breast Cancer-A Critical Review. J Young Pharm 16(3):416\u2013424. https:\/\/doi.org\/10.5530\/jyp.2024.16.54","journal-title":"J Young Pharm"},{"issue":"1","key":"12069_CR79","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12943-025-02410-x","volume":"24","author":"P Kesharwani","year":"2025","unstructured":"Kesharwani P, Kumar V, Goh KW, Gupta G, Alsayari A, Wahab S et al (2025) PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy. Mol Cancer 24(1):205. https:\/\/doi.org\/10.1186\/s12943-025-02410-x","journal-title":"Mol Cancer"},{"issue":"11","key":"12069_CR80","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.3390\/ijms25115771","volume":"25","author":"EW Li","year":"2024","unstructured":"Li EW, Tran NYK, McCulloch D, Krigstein M, Catalano A, Othman J et al (2024) FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia. Int J Mol Sci 25(11):5771. https:\/\/doi.org\/10.3390\/ijms25115771","journal-title":"Int J Mol Sci"},{"issue":"9","key":"12069_CR81","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.2021015246","volume":"141","author":"M Roas","year":"2023","unstructured":"Roas M, Vick B, Kasper MA, Able M, Polzer H, Gerlach M et al (2023) Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML. Blood 141(9):1023\u20131035. https:\/\/doi.org\/10.1182\/blood.2021015246","journal-title":"Blood"},{"issue":"2","key":"12069_CR82","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1073\/pnas.1016065108","volume":"108","author":"S Stangl","year":"2011","unstructured":"Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I, Sievert W et al (2011) Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci 108(2):733\u2013738. https:\/\/doi.org\/10.1073\/pnas.1016065108","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"12069_CR83","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/chemengineering9030056","volume":"9","author":"S Basak","year":"2025","unstructured":"Basak S, Das TK (2025) Liposome-Based Drug Delivery Systems: From Laboratory Research to Industrial Production\u2014Instruments and Challenges. ChemEngineering 9(3):56. https:\/\/doi.org\/10.3390\/chemengineering9030056","journal-title":"ChemEngineering"},{"key":"12069_CR84","doi-asserted-by":"publisher","first-page":"1177151","DOI":"10.3389\/fbioe.2023.1177151","volume":"11","author":"X Cheng","year":"2023","unstructured":"Cheng X, Xie Q, Sun Y (2023) Advances in nanomaterial-based targeted drug delivery systems. Front Bioeng Biotechnol 11:1177151. https:\/\/doi.org\/10.3389\/fbioe.2023.1177151","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"12069_CR85","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1261\/rna.079507.122","volume":"29","author":"SF Dowdy","year":"2023","unstructured":"Dowdy SF (2023) Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem? RNA 29(4):396\u2013401. https:\/\/doi.org\/10.1261\/rna.079507.122","journal-title":"RNA"},{"key":"12069_CR86","doi-asserted-by":"publisher","unstructured":"Liu Z, Dong Y (2026) Quantifying endosomal escape in vivo to guide lipid nanoparticle design. Nat Biotechnol 11. https:\/\/doi.org\/10.1038\/s41587-026-03047-x","DOI":"10.1038\/s41587-026-03047-x"},{"issue":"11","key":"12069_CR87","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00044-025-03454-w","volume":"34","author":"K Dey","year":"2025","unstructured":"Dey K, Erwin N, Molina N, Chen H, He M, Zheng G (2025) Nano-TPD: Using nanoparticle-based systems to improve the delivery and therapeutic effect of targeted protein degraders. Med Chem Res 34(11):2205\u20132227. https:\/\/doi.org\/10.1007\/s00044-025-03454-w","journal-title":"Med Chem Res"},{"key":"12069_CR88","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejpb.2018.05.034","volume":"129","author":"LMP Vermeulen","year":"2018","unstructured":"Vermeulen LMP, De Smedt SC, Remaut K, Braeckmans K (2018) The proton sponge hypothesis: Fable or fact? Eur J Pharm Biopharm 129:184\u2013190. https:\/\/doi.org\/10.1016\/j.ejpb.2018.05.034","journal-title":"Eur J Pharm Biopharm"},{"issue":"8","key":"12069_CR89","doi-asserted-by":"publisher","first-page":"jcs254185","DOI":"10.1242\/jcs.254185","volume":"134","author":"FM Skjeldal","year":"2021","unstructured":"Skjeldal FM, Haugen LH, Mateus D, Frei DM, R\u00f8dseth AV, Hu X et al (2021) De novo formation of early endosomes during Rab5-to-Rab7a transition. J Cell Sci 134(8):jcs254185. https:\/\/doi.org\/10.1242\/jcs.254185","journal-title":"J Cell Sci"},{"issue":"1","key":"12069_CR90","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1038\/s41467-023-40428-1","volume":"14","author":"HM York","year":"2023","unstructured":"York HM, Joshi K, Wright CS, Kreplin LZ, Rodgers SJ, Moorthi UK et al (2023) Deterministic early endosomal maturations emerge from a stochastic trigger-and-convert mechanism. Nat Commun 14(1):4652. https:\/\/doi.org\/10.1038\/s41467-023-40428-1","journal-title":"Nat Commun"},{"issue":"3","key":"12069_CR91","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s13346-021-00972-z","volume":"12","author":"R Lopes","year":"2022","unstructured":"Lopes R, Shi K, Fonseca NA, Gama A, Ramalho JS, Almeida L et al (2022) Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin. Drug Deliv Transl Res 12(3):629\u2013646. https:\/\/doi.org\/10.1007\/s13346-021-00972-z","journal-title":"Drug Deliv Transl Res"},{"issue":"7","key":"12069_CR92","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/pharmaceutics17070927","volume":"17","author":"S Alamos-Musre","year":"2025","unstructured":"Alamos-Musre S, Beltr\u00e1n-Chacana D, Moyano J, M\u00e1rquez-Miranda V, Duarte Y, Miranda-Rojas S et al (2025) From Structure to Function: The Promise of PAMAM Dendrimers in Biomedical Applications. Pharmaceutics 17(7):927. https:\/\/doi.org\/10.3390\/pharmaceutics17070927","journal-title":"Pharmaceutics"},{"issue":"1","key":"12069_CR93","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s11033-025-10943-z","volume":"52","author":"R Puspita","year":"2025","unstructured":"Puspita R, Jusuf AA (2025) Systematic review of exosomes derived from various stem cell sources: function and therapeutic potential in disease modulation. Mol Biol Rep 52(1):842. https:\/\/doi.org\/10.1007\/s11033-025-10943-z","journal-title":"Mol Biol Rep"},{"key":"12069_CR94","doi-asserted-by":"publisher","unstructured":"Strus B, Szterk A, PLGA-PEG\u2010PLGA, Polymer (2025) From synthesis to advanced pharmaceutical applications. In: Li W (ed) Adv polym technol, p. 8899828. https:\/\/doi.org\/10.1155\/adv\/8899828","DOI":"10.1155\/adv\/8899828"},{"key":"12069_CR95","doi-asserted-by":"publisher","first-page":"124057","DOI":"10.1016\/j.ijpharm.2024.124057","volume":"655","author":"SN Turkmen Koc","year":"2024","unstructured":"Turkmen Koc SN, Rezaei Benam S, Aral IP, Shahbazi R, Ulubayram K (2024) Gold nanoparticles-mediated photothermal and photodynamic therapies for cancer. Int J Pharm 655:124057. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124057","journal-title":"Int J Pharm"},{"issue":"5","key":"12069_CR96","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1515\/mr-2023-0029","volume":"3","author":"QTH Shubhra","year":"2023","unstructured":"Shubhra QTH (2023) Iron oxide nanoparticles in magnetic drug targeting and ferroptosis-based cancer therapy. Med Rev 3(5):444\u2013447. https:\/\/doi.org\/10.1515\/mr-2023-0029","journal-title":"Med Rev"},{"issue":"1","key":"12069_CR97","doi-asserted-by":"publisher","first-page":"17","DOI":"10.34172\/apb.2022.007","volume":"12","author":"S Pandey","year":"2022","unstructured":"Pandey S, Shaikh F, Gupta A, Tripathi P, Yadav JS (2022) A Recent Update: Solid Lipid Nanoparticles for Effective Drug Delivery. Adv Pharm Bull 12(1):17\u201333. https:\/\/doi.org\/10.34172\/apb.2022.007","journal-title":"Adv Pharm Bull"},{"key":"12069_CR98","doi-asserted-by":"publisher","unstructured":"Singh B, Lohan S, Sandhu PS, Jain A, Mehta SK (2016) Functionalized carbon nanotubes and their promising applications in therapeutics and diagnostics. Nanobiomaterials in Medical Imaging, pp 455\u2013478. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323417365000157https:\/\/doi.org\/10.1016\/B978-0-323-41736-5.00015-7","DOI":"10.1016\/B978-0-323-41736-5.00015-7"},{"issue":"8","key":"12069_CR99","doi-asserted-by":"publisher","first-page":"e10293","DOI":"10.1002\/adma.202510293","volume":"38","author":"Q Wu","year":"2026","unstructured":"Wu Q, Yao X, Duan X, Chen X, Zhang J (2026) Nanomedicine Reimagined: Translational Strategies for Precision Tumor Theranostics. Adv Mater 38(8):e10293. https:\/\/doi.org\/10.1002\/adma.202510293","journal-title":"Adv Mater"},{"issue":"1","key":"12069_CR100","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/epigenomes7010006","volume":"7","author":"A Kim","year":"2023","unstructured":"Kim A, Mo K, Kwon H, Choe S, Park M, Kwak W et al (2023) Epigenetic Regulation in Breast Cancer: Insights on Epidrugs. Epigenomes 7(1):6. https:\/\/doi.org\/10.3390\/epigenomes7010006","journal-title":"Epigenomes"},{"issue":"10","key":"12069_CR101","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1080\/21645515.2016.1190057","volume":"12","author":"IV Guzhova","year":"2016","unstructured":"Guzhova IV, Margulis BA (2016) HSP70-based anti-cancer immunotherapy. Hum Vaccines Immunother 12(10):2529\u20132535. https:\/\/doi.org\/10.1080\/21645515.2016.1190057","journal-title":"Hum Vaccines Immunother"},{"issue":"7471","key":"12069_CR102","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature12564","volume":"502","author":"LM McShane","year":"2013","unstructured":"McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM et al (2013) Criteria for the use of omics-based predictors in clinical trials. Nature 502(7471):317\u2013320. https:\/\/doi.org\/10.1038\/nature12564","journal-title":"Nature"},{"issue":"1","key":"12069_CR103","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12876-021-01990-4","volume":"21","author":"X Wang","year":"2021","unstructured":"Wang X, Xie L, Zhu L (2021) Clinicopathological significance of HSP70 expression in gastric cancer: a systematic review and meta-analysis. BMC Gastroenterol 21(1):437. https:\/\/doi.org\/10.1186\/s12876-021-01990-4","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"12069_CR104","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.3390\/biomedicines11082276","volume":"11","author":"A Xanthopoulos","year":"2023","unstructured":"Xanthopoulos A, Samt AK, Guder C, Taylor N, Roberts E, Herf H, Messner V, Trill A, Holzmann KLK, Kiechle M, Seifert-Klauss V, Zschaeck S, Schatka I, Tauber R, Schmidt R, Enste K, Pockley AG, Lobinger D, Multhoff G (2023) Hsp70-A Universal Biomarker for Predicting Therapeutic Failure in Human Female Cancers and a Target for CTC Isolation in Advanced Cancers. Biomedicines 11(8):2276. https:\/\/doi.org\/10.3390\/biomedicines11082276","journal-title":"Biomedicines"},{"key":"12069_CR105","unstructured":"Multhoff G (2018) Hsp70 based combination therapy. European Patent EP3675877A1. European Patent Office"},{"key":"12069_CR106","doi-asserted-by":"publisher","first-page":"119785","DOI":"10.1016\/j.carbpol.2022.119785","volume":"294","author":"D Gao","year":"2022","unstructured":"Gao D, Asghar S, Ye J, Zhang M, Hu R, Wang Y et al (2022) Dual-targeted enzyme-sensitive hyaluronic acid nanogels loading paclitaxel for the therapy of breast cancer. Carbohydr Polym 294:119785. https:\/\/doi.org\/10.1016\/j.carbpol.2022.119785","journal-title":"Carbohydr Polym"},{"key":"12069_CR107","doi-asserted-by":"publisher","first-page":"142559","DOI":"10.1016\/j.ijbiomac.2025.142559","volume":"308","author":"M Li","year":"2025","unstructured":"Li M, Chu K, Zhou Q, Wang H, Zhang W, Zhang Y et al (2025) Dual-drug loaded hyaluronic acid conjugates coated polydopamine nanodrugs for synergistic chemo-photothermal therapy in triple negative breast cancer. Int J Biol Macromol 308:142559. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.142559","journal-title":"Int J Biol Macromol"},{"key":"12069_CR108","unstructured":"Breitenkamp K, Sill K, Skaff H, Breitenkamp R (2006) Polymeric micelles for drug delivery. United States patent US20060240092A1"},{"key":"12069_CR109","doi-asserted-by":"publisher","first-page":"102124","DOI":"10.1016\/j.nano.2019.102124","volume":"24","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Alakhova DY, Zhao X, Band V, Batrakova EV, Kabanov AV (2020) Eradication of cancer stem cells in triple negative breast cancer using doxorubicin\/pluronic polymeric micelles. Nanomed Nanotechnol Biol Med 24:102124. https:\/\/doi.org\/10.1016\/j.nano.2019.102124","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"10","key":"12069_CR110","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2174\/1568026623666230303101810","volume":"23","author":"X Zhang","year":"2023","unstructured":"Zhang X, Dong N, Hu X (2023) Wnt\/\u03b2-catenin Signaling Inhibitors. Curr Top Med Chem 23(10):880\u2013896. https:\/\/doi.org\/10.2174\/1568026623666230303101810","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"12069_CR111","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1038\/s41467-022-34744-1","volume":"13","author":"M Panagi","year":"2022","unstructured":"Panagi M, Mpekris F, Chen P, Voutouri C, Nakagawa Y, Martin JD et al (2022) Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models. Nat Commun 13(1):7165. https:\/\/doi.org\/10.1038\/s41467-022-34744-1","journal-title":"Nat Commun"},{"issue":"2","key":"12069_CR112","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ijpharm.2016.07.060","volume":"511","author":"W Chen","year":"2016","unstructured":"Chen W, di liang, Yang S, Li F, Li Jzhao, Yuan Zqiang, Zhu W, jing et al (2016) Tumor microenvironment-responsive micelles for pinpointed intracellular release of doxorubicin and enhanced anti-cancer efficiency. Int J Pharm 511(2):728\u2013740. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.07.060","journal-title":"Int J Pharm"},{"issue":"36","key":"12069_CR113","doi-asserted-by":"publisher","first-page":"8383","DOI":"10.1039\/D0TB01140A","volume":"8","author":"L Li","year":"2020","unstructured":"Li L, Liu T, Liao JX, Zhang ZY, Song DB, Wang GH (2020) Dual-responsive TPGS crosslinked nanocarriers to overcome multidrug resistance. J Mater Chem B 8(36):8383\u20138394. https:\/\/doi.org\/10.1039\/D0TB01140A","journal-title":"J Mater Chem B"},{"key":"12069_CR114","unstructured":"Orlowski RZ, Jones RJ, Bover LC, Gyuris J, Miller J (2021) Monoclonal antibodies targeting HSP70 and therapeutic uses thereof. World patent WO2021195557A2"},{"issue":"15suppl","key":"12069_CR115","doi-asserted-by":"publisher","first-page":"e14081","DOI":"10.1200\/JCO.2016.34.15_suppl.e14081","volume":"34","author":"T Hamaguchi","year":"2016","unstructured":"Hamaguchi T, Doi T, Shitara K, Iwasa S, Shimada Y, Harda M et al (2016) A phase I study of NC-6004, a micellar formulation of cisplatin, in combination with gemcitabine in Japanese patients with advanced solid tumors. J Clin Oncol 34(15suppl):e14081\u2013e14081. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.e14081","journal-title":"J Clin Oncol"},{"issue":"20","key":"12069_CR116","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.2217\/fon-2021-1609","volume":"18","author":"N Skorupan","year":"2022","unstructured":"Skorupan N, Ahmad MI, Steinberg SM, Trepel JB, Cridebring D, Han H et al (2022) A phase II trial of the super-enhancer inhibitor Minnelide\u2122 in advanced refractory adenosquamous carcinoma of the pancreas. Future Oncol 18(20):2475\u20132481. https:\/\/doi.org\/10.2217\/fon-2021-1609","journal-title":"Future Oncol"},{"key":"12069_CR117","unstructured":"Multhoff G (2019) inventor; Multimmune GmbH, assignee. Hsp70 based combination therapy. WO patent WO2019043170A1"},{"issue":"4","key":"12069_CR118","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/biom13040601","volume":"13","author":"K Zhao","year":"2023","unstructured":"Zhao K, Zhou G, Liu Y, Zhang J, Chen Y, Liu L et al (2023) HSP70 Family in Cancer: Signaling Mechanisms and Therapeutic Advances. Biomolecules 13(4):601. https:\/\/doi.org\/10.3390\/biom13040601","journal-title":"Biomolecules"},{"issue":"15","key":"12069_CR119","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.3390\/ijms21155298","volume":"21","author":"S Tukaj","year":"2020","unstructured":"Tukaj S (2020) Heat Shock Protein 70 as a Double Agent Acting Inside and Outside the Cell: Insights into Autoimmunity. Int J Mol Sci 21(15):5298. https:\/\/doi.org\/10.3390\/ijms21155298","journal-title":"Int J Mol Sci"},{"key":"12069_CR120","doi-asserted-by":"publisher","unstructured":"Kosaka Y, Saeki T, Takano T, Aruga T, Yamashita T, Masuda N et al (2022) Multicenter randomized open-label phase II clinical study comparing outcomes of NK105 and paclitaxel in advanced or recurrent breast cancer. Int J Nanomed 17:4567\u20134578. https:\/\/doi.org\/10.2147\/IJN.S372477","DOI":"10.2147\/IJN.S372477"},{"issue":"7","key":"12069_CR121","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/cas.12960","volume":"107","author":"N Nishiyama","year":"2016","unstructured":"Nishiyama N, Matsumura Y, Kataoka K (2016) Development of polymeric micelles for targeting intractable cancers. Cancer Sci 107(7):867\u2013874. https:\/\/doi.org\/10.1111\/cas.12960","journal-title":"Cancer Sci"},{"issue":"2","key":"12069_CR122","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1039\/D4PM00263F","volume":"2","author":"A Dhiman","year":"2025","unstructured":"Dhiman A, Shah Y, Rana D, Garkhal K (2025) Comprehensive review on glioblastoma: nanotechnology, immunotherapy and combined therapeutic approaches. RSC Pharm 2(2):207\u2013234. https:\/\/doi.org\/10.1039\/D4PM00263F","journal-title":"RSC Pharm"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12069-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12069-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12069-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:01:30Z","timestamp":1780732890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12069-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12069"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12069-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"898"}}